financials

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst takes on their favorite stocks by...

The most oversold stocks in the financials sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action...

As of Sept. 6, 2024, four stocks in the financials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst takes on their favorite stocks by...

As of Aug 13, 2024, two stocks in the financials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when...

A market strategist is providing insight into which sectors could benefit based on whether Donald Trump or Joe Biden wins the 2024 presidential election. What Happened: There is a lot of focus on electric vehicles ahead of the 2024 election with a win by Trump seen as a negative for the sector, but...

The financial sector looks favorable after a recent earnings report from JPMorgan Chase (NYSE:JPM) and other factors, a market strategist told Benzinga. What Happened: An earnings report from JPMorgan was strong and could lead the financial sector going forward, Freedom Capital Markets Chief Global...

The Financial Select Sector SPDR Fund (NYSE:XLF), an exchange-traded fund that provides exposure to a wide range of financial companies in the U.S., on Friday reached its highest level since March 7, 2023. This represented a complete recovery from the selloff caused by the collapse of Silicon...

In the midst of the financial crisis in October 2008, Berkshire Hathaway Inc. CEO Warren Buffett made a significant late-night phone call to the then-Treasury Secretary Henry "Hank" Paulson. Buffett aimed to share an idea that could potentially revive the struggling economy. Don't Miss: Why Silicon...

Clinical-stage biopharma company Seelos Therapeutics Inc. (NASDAQ: SEEL) reported financial results and clinical updates corresponding to the first quarter ended March 31, 2023. Quarterly numbers show: Total cash and cash equivalents of $14.1 million as of March 31, 2023, compared to the $15.5...

Natural psychedelics drug developer Filament Health Corp. (OTCQB: FLHLF) shared its interim financial results and further business highlights for the first quarter ended March 31, 2023. These results were assembled by the company’s management and were not reviewed by the independent...

The U.S. stock market got off to a shaky start in May. The S&P 500 index, closely tracked by the SPDR S&P 500 Trust ETF (ARCA: SPY), is poised to end its second consecutive week of losses for the first time since mid-February as the debt-limit stalemate weighed on sentiment. As of...

Mental healthcare biotech company advancing psilocybin therapy COMPASS Pathways plc (NASDAQ: CMPS) reported its financial results for the first quarter 2023 ended March 31, 2023 and updated on recent business and clinical progresses. In numbers: Cash and cash equivalents totaled $117.1 million as...

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights. Consolidated quarterly financials: Cash, cash equivalents and short-term investments of a total $249.9...

Clinical-stage biopharma company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has reported its unaudited financial results for the quarter ended March 31, 2023, and shared the period’s business highlights. Numbers show: Cash and cash equivalents totaled $129.4 million as of March 31, an...